References: 

• 1. Blikslager AT, Moeser AJ, Gookin JL, et al. (2007) Restoration of barrier function in injured intestinal mucosa. Physiol Rev 87: 545.    
• 2. Podolsky DK (1999) V. Innate mechanisms of mucosal defense and repair: The best offense is a good defense. Am J Physiol 277: G495–G499.
• 3. Kunzelmann K, Mall M (2002) Electrolyte transport in the mammalian colon: Mechanisms and Implications for disease. Physiol Rev 82: 245–289.    
• 4. Ferraris RP, Diamond J (1997) Regulation of intestinal sugar transport. Physiol Rev 77: 257–302.    
• 5. Groschwitz KR, Hogan SP (2009) Intestinal barrier function: Molecular regulation and disease pathogenesis. J Allergy Clin Immunol 124: 3–22.    
• 6. Bischoff S, Barbara G, Buurman W, et al. (2014) Intestinal permeability-A new target for disease prevention and therapy. BMC Gastroenterol 14: 189–214.    
• 7. Van Itallie CM, Holmes J, Bridges A, et al. (2008) The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Sci 121: 298–305.    
• 8. Ulluwishewa D, Anderson RC, Mcnabb WC, et al. (2011) Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 141: 769–776.    
• 9. De Magistris L, Picardi A, Sapone A, et al. (2014) Intestinal barrier in autism, In: Patel VB (ed.), Comprehensive guide to autism, New York: Springer, 123.
• 10. Catassi C, Fasano A (2008) Celiac disease. Curr Opin Gastroenterol 24: 687–691.    
• 11. Bjarnason I, Macpherson A, Hollander D (1995) Intestinal permeability: An overview. Gastroenterology 108: 1566–1581.    
• 12. Fasano A (2011) Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity and cancer. Physiol Rev 91: 151–175.    
• 13. Lerner A, Matthias T (2015) Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev 14: 479–489.    
• 14. Siniscalco D, Cirillo A, Bradstreet JJ, et al. (2013) Epigenetic findings in autism: New perspectives for therapy. Int J Environ Res Public Health 10: 4261–4273.    
• 15. Siniscalco D, Antonucci N (2013) Possible use of Trichuris suis ova in autism spectrum disorders therapy. Med Hypotheses 81: 1–4.    
• 16. Wakefield AJ (2002) The gut-brain axis in childhood developmental disorders. J Pediatr Gastroenterol Nutr 34: S14–S17.    
• 17. Siniscalco D (2014) Gut bacteria-brain axis in autism. Autism 4: e124.
• 18. Siniscalco D, Antonucci N (2013) Involvement of dietary bioactive proteins and peptides in autism spectrum disorders. Curr Protein Pept Sci 14: 674–679.
• 19. Trivedi MS, Shah JS, Al-Mughairy S, et al. (2014) Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. J Nutr Biochem 25: 1011–1018.    
• 20. Frustaci A, Neri M, Cesario A, et al. (2012) Oxidative stress-related biomarkers in autism: Systematic review and meta-analyses. Free Radic Biol Med 52: 2128–2141.    
• 21. Melnyk S, Fuchs GJ, Schulz E, et al. (2012) Metabolic imbalance associated with methylation dys-regulation and oxidative damage in children with autism. J Autism Dev Disord 42: 367–377.    
• 22. Shattock P, Whiteley P (2002) Biochemical aspects in autism spectrum disorders: Updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets 6: 175–183.    
• 23. Siniscalco D, Sapone A, Giordano C, et al. (2013) Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J Autism Dev Disord 43: 2686–2695.    
• 24. Siniscalco D, Bradstreet JJ, Cirillo A, et al. (2014) The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages. J Neuroinflammation 11: 78.    
• 25. Fiorentino M, Sapone A, Senger S, et al. (2016) Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism 7: 49.    
• 26. Rose DR, Yang H, Serena G, et al. (2018) Differential immune responses and microbiota profiles in children with autism spectrum disorders and co-morbid gastrointestinal symptoms. Brain Behav Immun 70: 354–368.    
• 27. Lionetti E, Leonardi S, Franzonello C, et al. (2015) Gluten psychosis: Confirmation of a new clinical entity. Nutrients 7: 5532–5539.    
• 28. O'Mahony SM, Clarke G, Borre YE, et al. (2015) Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 277: 32–48.    
• 29. Theije CGMD, Koelink PJ, Korte-Bouws GA, et al. (2014) Intestinal inflammation in a murine model of autism spectrum disorders. Brain Behav Immun 37: 240–247.    
• 30. Baganz NL, Blakely RD (2013) A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci 4: 48–63.    
• 31. Van Elst K, Bruining H, Birtoli B, et al. (2014) Food for thought: Dietary changes in essential fatty acid ratios and the increase in autism spectrum disorders. Neurosci Biobehav Rev 45: 369–738.    
• 32. Halliwell B (2006) Oxidative stress and neurodegeneration: Where are we now? J Neurochem 97: 1634–1658.    
• 33. Cartocci V, Catallo M, Tempestilli M, et al. (2018) Altered brain cholesterol/isoprenoid metabolism in a rat model of autism spectrum disorders. Neuroscience 372: 27–37.    
• 34. Brigida AL, Schultz S, Cascone M, et al. (2017) Endocannabinod signal dysregulation in autism spectrum disorders: A correlation link between inflammatory state and neuro-immune alterations. Int J Mol Sci 18: 1425.    
• 35. Acharya N, Penukonda S, Shcheglova T, et al. (2017) Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proc Natl Acad Sci USA 114: 5005–5010.    
• 36. Gyires K, Zádori ZS (2016) Role of cannabinoids in gastrointestinal mucosal defense and inflammation. Curr Neuropharmacol 14: 935–951.    
• 37. Maríbauset S, Llopisgonzález A, Zazpe I, et al. (2016) Nutritional Impact of a Gluten-Free Casein-Free Diet in Children with Autism Spectrum Disorder. J Autism Dev Disord 46: 673–684.    
• 38. Iovene MR, Bombace F, Maresca R, et al. (2017) Intestinal Dysbiosis and Yeast Isolation in Stool of Subjects with Autism Spectrum Disorders. Mycopathologia 182: 349–363.    
• 39. Siniscalco D, Mijatovic T, Bosmans E, et al. (2016) Decreased Numbers of CD57 + CD3- Cells Identify Potential Innate Immune Differences in Patients with Autism Spectrum Disorder. Vivo 30: 83–89.
• 40. de Theije CG, Wopereis H, Ramadan M, et al. (2014) Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav Immun 37: 197–206.    
• 41. Needham BD, Tang W, Wu WL (2018) Searching for the gut microbial contributing factors to social behavior in rodent models of autism spectrum disorder. Dev Neurobiol 78: 474–499.    
• 42. Fung TC, Olson CA, Hsiao EY (2017) Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 20: 145–155.    
• 43. Santocchi E, Guiducci L, Fulceri F, et al. (2016) Gut to brain interaction in Autism Spectrum Disorders: A randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters. BMC Psychiatry 16: 183.    

show all references